OTCMKTS:ATBPD Antibe Therapeutics (ATBPD) Stock Price, News & Analysis → Oil Surge Predicted... But Are You Ready (From The Oxford Club) (Ad) Free ATBPD Stock Alerts $0.22 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.22▼$0.2250-Day Range$0.12▼$0.7852-Week Range$2.64▼$3.50VolumeN/AAverage Volume29,710 shsMarket Capitalization$83.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Antibe Therapeutics alerts: Email Address Ad Paradigm PressMy biggest AI fear (Do this before June 25th)These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.All the details are right here. About Antibe Therapeutics Stock (OTCMKTS:ATBPD)Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Read More ATBPD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATBPD Stock News HeadlinesApril 1, 2024 | marketwatch.comAntibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. RegulatorApril 1, 2024 | marketwatch.comAntibe Therapeutics Drug Otenaproxesul Placed on Clinical Hold by FDAMay 6, 2024 | Behind the Markets (Ad)Revealed: The Unknown Biotech Powering AI in HealthcareThe CEO of Google predicted this is "one of the most important things for humanity." We're standing at the brink of an AI revolution in medicine, a leap forward that will change the future medicine as we know it. If you're only watching tech giants like NVIDIA and Google for AI investments, you're missing the biggest opportunities... Because I've uncovered a little known biotech at the heart of this AI medical revolution.June 29, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Antibe Therapeutics (OtherATBPF), Terns Pharmaceuticals (TERN) and Aquestive Therapeutics (AQST)See More Headlines Receive ATBPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:ATBPD CUSIPN/A CIKN/A Webwww.antibethera.com Phone416 922 3460FaxN/AEmployees47Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,540,000.00 Net Margins-273.96% Pretax MarginN/A Return on Equity-150.49% Return on Assets-98.51% Debt Debt-to-Equity RatioN/A Current Ratio5.97 Quick Ratio5.42 Sales & Book Value Annual Sales$7.51 million Price / Sales11.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book2.16Miscellaneous Outstanding Shares387,000,000Free FloatN/AMarket Cap$83.44 million OptionableNot Optionable Beta0.57 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Daniel Marcel Legault (Age 62)Pres, CEO, Sec. & Director Dr. John Lawrence Wallace M.B.A. (Age 63)M.Sc., MSc, Ph.D., MBA, Founder, Chief Scientific Officer & Director Mr. Alain Wilson M.B.A.MBA, Chief Financial OfficerDr. David James Vaughan (Age 70)Chief Devel. Officer Mr. Scott Curtis C.F.A.M.Eng, CFA, Exec. VPMs. Christina Cameron B.B.A.VP of Investor RelationsMr. Philip SternVP of CommunicationsDr. Rami Batal M.B.A.Ph.D., Chief Commercial OfficerMs. Ella Korets Smith M.B.A.M.Sc., Head of Regional Bus. Devel.Dr. Joseph Stauffer (Age 54)Chief Medical Officer More ExecutivesKey CompetitorsSpero TherapeuticsNASDAQ:SPROLeap TherapeuticsNASDAQ:LPTXInflaRxNASDAQ:IFRXvTv TherapeuticsNASDAQ:VTVTOncolytics BiotechNASDAQ:ONCYView All Competitors ATBPD Stock Analysis - Frequently Asked Questions How have ATBPD shares performed in 2024? Antibe Therapeutics' stock was trading at $0.6820 at the beginning of 2024. Since then, ATBPD shares have decreased by 68.4% and is now trading at $0.2156. View the best growth stocks for 2024 here. How do I buy shares of Antibe Therapeutics? Shares of ATBPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ATBPD) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersNo experience to confident trader, meet my student…Wealth Builders InstituteBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressRevealed: The Unknown Biotech Powering AI in HealthcareBehind the MarketsOil Surge Predicted... But Are You ReadyThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceWarren Buffet Stockpiling Gold?Reagan Gold GroupControversial CEO explains new way to amass wealthStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.